Literature DB >> 8867523

Analgesic efficacy of the kappa-receptor agonist, enadoline, in dental surgery pain.

A C Pande1, R E Pyke, M Greiner, S A Cooper, R Benjamin, M W Pierce.   

Abstract

To study the analgesic efficacy of enadoline, a selective agonist of the kappa-opioid receptor, a double-blind, randomized comparison was made of enadoline versus placebo and a combination of acetaminophen-codeine in patients with pain after surgical extraction of impacted molar teeth. An initial study involving a comparison of enadoline, a combination, and placebo failed to show any analgesic effect of enadoline. Therefore, a second study with the same design but using higher doses of enadoline was conducted. Despite continued safety and tolerability even at the higher doses, enadoline could not be shown to be superior to placebo. The acetaminophen-codeine combination was significantly more effective than enadoline or placebo. Enadoline did not show analgesic efficacy in this study. Possible reasons for this lack of efficacy are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8867523     DOI: 10.1097/00002826-199619010-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  16 in total

1.  Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats.

Authors:  S Stevens Negus; Robert O'Connell; Ember Morrissey; Kejun Cheng; Kenner C Rice
Journal:  J Pharmacol Exp Ther       Date:  2011-11-29       Impact factor: 4.030

2.  75 years of opioid research: the exciting but vain quest for the Holy Grail.

Authors:  Alistair D Corbett; Graeme Henderson; Alexander T McKnight; Stewart J Paterson
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 3.  Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.

Authors:  L A Smith; R A Moore; H J McQuay; D Gavaghan
Journal:  BMC Med Res Methodol       Date:  2001-01-10       Impact factor: 4.615

4.  Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats.

Authors:  L P Legakis; L Karim-Nejad; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2020-05-08       Impact factor: 4.530

5.  Sex differences in kappa opioid receptor inhibition of latent postoperative pain sensitization in dorsal horn.

Authors:  Lilian Custodio-Patsey; Renée R Donahue; Weisi Fu; Joshua Lambert; Bret N Smith; Bradley K Taylor
Journal:  Neuropharmacology       Date:  2019-07-25       Impact factor: 5.250

Review 6.  Addressing the Opioid Crisis: The Importance of Choosing Translational Endpoints in Analgesic Drug Discovery.

Authors:  S Stevens Negus
Journal:  Trends Pharmacol Sci       Date:  2018-02-28       Impact factor: 14.819

7.  Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.

Authors:  Matthew L Lazenka; Megan J Moerke; E Andrew Townsend; Kevin B Freeman; F Ivy Carroll; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

Review 8.  Targeting multiple opioid receptors - improved analgesics with reduced side effects?

Authors:  Thomas Günther; Pooja Dasgupta; Anika Mann; Elke Miess; Andrea Kliewer; Sebastian Fritzwanker; Ralph Steinborn; Stefan Schulz
Journal:  Br J Pharmacol       Date:  2017-05-26       Impact factor: 8.739

9.  A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeys.

Authors:  Marc J Kaufman; Amy C Janes; Blaise deB Frederick; Melanie Brimson-Théberge; Yunjie Tong; Samuel B McWilliams; Ashley Bear; Timothy E Gillis; Katrina M Schrode; Perry F Renshaw; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2013-06-17       Impact factor: 3.157

10.  Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.

Authors:  Yi Zheng; Samuel Obeng; Bethany A Reinecke; Chongguang Chen; Palak S Phansalkar; David M Walentiny; Phillip M Gerk; Lee-Yuan Liu-Chen; Dana E Selley; Patrick M Beardsley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2019-11-16       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.